Divisions of Gastroenterology and Hepatology, University Hospitals, Geneva, Switzerland; Division of Clinical Pathology, University Hospitals, Geneva, Switzerland.
J Hepatol. 2014 Nov;61(1 Suppl):S69-78. doi: 10.1016/j.jhep.2014.08.003. Epub 2014 Nov 3.
The hepatitis C virus (HCV) is a major cause of chronic hepatitis, cirrhosis and hepatocellular carcinoma worldwide. A significant portion of the morbidity and mortality associated with HCV is a consequence of numerous HCV-associated comorbidities. Type 2 diabetes and atherosclerosis, two known complications of the metabolic syndrome, are noteworthy, because HCV has been suggested to play a role in their pathogenesis. In addition, HCV also causes steatosis, which may increase the risk of cardiovascular events. This review summarizes the evidence supporting the association between HCV and steatosis, insulin resistance/type 2 diabetes and cardiovascular morbidity and mortality. Their diagnostic, prognostic and management aspects are discussed.
丙型肝炎病毒(HCV)是全球慢性肝炎、肝硬化和肝细胞癌的主要病因。与 HCV 相关的许多合并症是导致其发病率和死亡率的重要原因。2 型糖尿病和动脉粥样硬化是代谢综合征的两个已知并发症,值得注意,因为 HCV 被认为在其发病机制中起作用。此外,HCV 还会导致脂肪变性,这可能会增加心血管事件的风险。这篇综述总结了支持 HCV 与脂肪变性、胰岛素抵抗/2 型糖尿病以及心血管发病率和死亡率之间关联的证据。还讨论了它们的诊断、预后和管理方面。